Table 1. Baseline characteristics of patients with chronic heart failure by NYHA functional class.
| Characteristics | General sample (n = 37) |
1st group I and II NYHA FC of CHF (mild CHF) (n = 23) |
2nd group III NYHA FC of CHF (moderate-to-severe CHF) (n = 14) |
P |
| 1 | 2 | |||
| Data are presented as median (Q1; Q3) or n (%). CHF: chronic heart failure. | ||||
| Age, yrs | 62.0 (51.0; 66.0) | 62.0 (56.0; 66.0) | 59.0 (49.0; 70.0) | 0.80 |
| Male | 28 (75.7%) | 20 (87.0%) | 8 (57.1%) | 0.04 |
| Hypertension, | 31 (83.8%) | 18 (78.3%) | 13 (92.9%) | 0.24 |
| Obesity | 15 (40.5 %) | 10 (43.5%) | 5 (35.7%) | 0.64 |
| Diabetes mellitus | 8 (21.6%) | 4 (17.4%) | 4 (28.6%) | 0.42 |
| Myocardial infarction | 14 (37.8%) | 6 (26.1%) | 8 (57.1%) | 0.06 |
| Body mass index, kg/m2 | 28.0 (22.6; 34.6) | 29.0 (22.6; 33.4) | 26.5 (23.6; 35.5) | 0.75 |
| Angiotensin-converting enzyme inhibitors/ Angiotensin II receptor blockers |
13 (35.1%) | 9 (39.1%) | 4 (28.6%) | 0.51 |
| Beta-blocker | 31 (83.8%) | 21 (91.3%) | 10 (71.4%) | 0.11 |
| Anticoagulation | 18 (48.6%) | 11 (47.8%) | 7 (50.0%) | 0.90 |
| Anti-diabetic | 11 (29.7%) | 6 (26.1%) | 5 (35.7%) | 0.53 |
| Statin | 29 (78.4%) | 17 (73.9%) | 12 (85.7%) | 0.40 |
| Left ventricle ejection fraction, % | 35.0% (29.0%; 45.0%) | 36.0% (33.0%; 48.0%) | 32.0% (25.0%; 39.0%) | 0.09 |
| Fasting plasma glucose, mmol/L | 5.7 (5.0; 6.1) | 5.3 (4.9; 6.0) | 5.8 (5.6; 6.9) | 0.07 |
| Total cholesterol, mmol/L | 4.1 (3.4; 4.9) | 4.0 (3.3; 4.9) | 4.1 (3.7; 4.8) | 0.71 |
| Triglycerides, mmol/L | 1.3 (0.9; 1.9) | 1.3 (0.9; 1.8) | 1.3 (0.9; 1.9) | 0.91 |